Australian biotech market today 16.03.09
Monday, 16 March, 2009
Pharma and biotech stocks were up 1 per cent at 3pm, compared to a minimal rise in the All Ordinaries.
Cochlear (ASX:COH) was up $1 to $49.91 per share following an excellent half-year report, which showed total revenues increased by 19 per cent and sales were up 22 per cent.
CSL (ASX:CSL) was up 38c to $33.38, and the last of the Big Three, Resmed (ASX:RMD) was down 10c.
Sonic Healthcare (ASX:SHL) is up a healthy 50c while Avexa (ASX:AVX) is up 16 per cent to 8c a share following good news from its Phase IIb trial of apricitabine in HIV patients.
Alchemia (ASX:ACL) is up another cent to 24c and Biota (ASX:BTA) is up slightly.
Biotron (ASX:BIT), a spin-out from ANU’s John Curtin School of Medical Research which is in early phase trials for an anti-viral for hepatitis C, is down 1c. Biotron was hit hard by the cancellation of the Commercial Ready scheme and is in the middle of a capital raising scheme.
Novogen (ASX:NRT) was up 4c to recover last week’s loss. ChemGenex (ASX:CXS) was down slightly to 43c, while Cytopia (ASX:CYT), Healthscope (ASX:HSP) and Phosphagenics (ASX:POH) were up slightly.
Life Therapeutics (ASX:LFE) is worth lolly money at 5c a share.
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
